Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.59 |
| ▸ | ALDH1A3 | P47895 | 1/20 | 0.53 |
| ▸ | PPARG | P37231 | 15/20 | 0.51 |
| ▸ | PPARA | Q07869 | 15/20 | 0.51 |
| ▸ | DRD1 | P21728 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1695379 | 0.89 | ALDH1A3 (0.51) | SMN1; SMN2ALDH1A3PPARGPPARADRD1 | |
| SCHEMBL2560941 | 0.87 | PPARG (0.60) | SMN1; SMN2ALDH1A3PPARGPPARA | |
| SCHEMBL8980166 | 0.85 | SMN1; SMN2 (0.58) | SMN1; SMN2PPARGPPARA | |
| SCHEMBL2557160 | 0.85 | ALDH1A3 (0.51) | SMN1; SMN2ALDH1A3PPARGPPARADRD1 | |
| SCHEMBL1011104 | 0.83 | SMN1; SMN2 (0.55) | SMN1; SMN2PPARGPPARAALDH1A1 | |
| SCHEMBL2174551 | 0.83 | SMN1; SMN2 (0.55) | SMN1; SMN2PPARGPPARAALDH1A1 | |
| SCHEMBL11550284 | 0.82 | SMN1; SMN2 (0.67) | SMN1; SMN2PPARGPPARA | |
| SCHEMBL8935859 | 0.81 | SMN1; SMN2 (0.70) | SMN1; SMN2PPARGPPARA | |
| SCHEMBL1745447 | 0.81 | PPARG (0.66) | SMN1; SMN2PPARGPPARA | |
| SCHEMBL433427 | 0.81 | SMN1; SMN2 (0.65) | SMN1; SMN2PPARGPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| US-11225655-B2 | Bi-functional complexes and methods for making and using such complexes | NUEVOLUTION A/S (DK) | 2022-01-18 | — | — | US | disclosed |
| EP-3540059-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | Nuevolution A/S (DK) | 2019-09-18 | — | — | EP | disclosed |
| EP-2558577-B1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION AS (DK) | 2018-12-12 | — | — | EP | disclosed |
| US-20130281324-A1 | BI-FUNCTINAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2013-10-24 | — | — | US | disclosed |
| EP-2558577-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | Nuevolution A/S (DK) | 2013-02-20 | — | — | EP | disclosed |
| WO-2011127933-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2011-10-20 | — | — | WO | disclosed |
| WO-2011009826-A2 | NOVEL CHALCONE DERIVATIVES WITH CYTOTOXIC ACTIVITY | ADAMED Sp.z o.o. (PL) | 2011-01-27 | — | — | WO | disclosed |
| US-20070099876-A1 | Target directed chemotherapy of tumours of the sexual organs | TRIN GMBH (CH) | 2007-05-03 | — | — | US | disclosed |
| WO-2005051381-A1 | Substituted urea-octatydroindols as antagonists of melanin concentrating hormone receptor 1 (MCH1R) | BIOVITRUM AB (SE) | 2005-06-09 | — | — | WO | disclosed |
| US-20050070558-A1 | 6-Phenyldihydropyrrolopyrimidinedione derivatives | ALMIRALL PRODESFARMA S.A. (ES) | 2005-03-31 | — | — | US | disclosed |
| EP-1409489-A1 | 6-PHENYLDIHYDROPYRROLOPYRIMIDINEDIONE DERIVATIVES | Almirall Prodesfarma, S.A. (ES) | 2004-04-21 | — | — | EP | disclosed |
| WO-2003000694-A1 | 6-PHENYLDIHYDROPYRROLOPYRIMIDINEDIONE DERIVATIVES | ALMIRALL PRODESFARMA S.A. (ES) | 2003-01-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070099876-A1 | Target directed chemotherapy of tumours of the sexual organs | GPER1, SHBG, GNRHR | SMN1; SMN2 4319/4885ALDH1A3 1177/4885PPARG 2172/4885 |
| US-20050070558-A1 | 6-Phenyldihydropyrrolopyrimidinedione derivatives | ADORA1, ADORA2A, P2RY10 | SMN1; SMN2 3868/4885ALDH1A3 1258/4885PPARG 449/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.